Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31false2024-01-01falseManufacturing within the medical industry81falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 11335956 2024-01-01 2024-12-31 11335956 2023-05-01 2023-12-31 11335956 2024-12-31 11335956 2023-12-31 11335956 c:Director2 2024-01-01 2024-12-31 11335956 d:PlantMachinery 2024-01-01 2024-12-31 11335956 d:PlantMachinery 2024-12-31 11335956 d:PlantMachinery 2023-12-31 11335956 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 11335956 d:MotorVehicles 2024-01-01 2024-12-31 11335956 d:MotorVehicles 2024-12-31 11335956 d:MotorVehicles 2023-12-31 11335956 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 11335956 d:OfficeEquipment 2024-01-01 2024-12-31 11335956 d:OfficeEquipment 2024-12-31 11335956 d:OfficeEquipment 2023-12-31 11335956 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 11335956 d:ComputerEquipment 2024-01-01 2024-12-31 11335956 d:ComputerEquipment 2024-12-31 11335956 d:ComputerEquipment 2023-12-31 11335956 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 11335956 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 11335956 d:CopyrightsPatentsTrademarksServiceOperatingRights 2024-01-01 2024-12-31 11335956 d:CopyrightsPatentsTrademarksServiceOperatingRights 2024-12-31 11335956 d:CopyrightsPatentsTrademarksServiceOperatingRights 2023-12-31 11335956 d:CurrentFinancialInstruments 2024-12-31 11335956 d:CurrentFinancialInstruments 2023-12-31 11335956 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 11335956 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 11335956 d:ShareCapital 2024-12-31 11335956 d:ShareCapital 2023-12-31 11335956 d:SharePremium 2024-12-31 11335956 d:SharePremium 2023-12-31 11335956 d:RetainedEarningsAccumulatedLosses 2024-12-31 11335956 d:RetainedEarningsAccumulatedLosses 2023-12-31 11335956 c:OrdinaryShareClass1 2024-01-01 2024-12-31 11335956 c:OrdinaryShareClass1 2024-12-31 11335956 c:OrdinaryShareClass1 2023-12-31 11335956 c:OrdinaryShareClass2 2024-01-01 2024-12-31 11335956 c:OrdinaryShareClass2 2024-12-31 11335956 c:FRS102 2024-01-01 2024-12-31 11335956 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 11335956 c:FullAccounts 2024-01-01 2024-12-31 11335956 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 11335956 d:CopyrightsPatentsTrademarksServiceOperatingRights d:ExternallyAcquiredIntangibleAssets 2024-01-01 2024-12-31 11335956 2 2024-01-01 2024-12-31 11335956 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 11335956









FLUIDIC SCIENCES LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
FLUIDIC SCIENCES LIMITED
REGISTERED NUMBER: 11335956

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

FIXED ASSETS
  

Tangible assets
 5 
56,832
-

Intangible assets
 4 
-
-

  
56,832
-

CURRENT ASSETS
  

Stocks
  
52,528
-

Debtors: amounts falling due within one year
 6 
277,562
-

Cash at bank and in hand
  
343,339
1,040

  
673,429
1,040

Creditors: amounts falling due within one year
 7 
(52,372)
(1,028)

NET CURRENT ASSETS
  
 
 
621,057
 
 
12

TOTAL ASSETS LESS CURRENT LIABILITIES
  
677,889
12

  

NET ASSETS
  
677,889
12


CAPITAL AND RESERVES
  

Called up share capital 
 8 
1,009,093
1

Share premium account
  
486,909
-

Profit and loss account
  
(818,113)
11

  
677,889
12


Page 1

 
FLUIDIC SCIENCES LIMITED
REGISTERED NUMBER: 11335956
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




A Lovatt
Director

Date: 26 June 2025

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


GENERAL INFORMATION

Fluidic Sciences Limited is a private company limited by shares and incorporated in England and Wales. Its registered office is 27 Jarman Way, Royston, Hertfordshire, SG8 5HW.
The Company commenced trading in May 2024, having previously been dormant but having then acquired the assets of a separate company that had entered administration. 

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.3

TURNOVER

Turnover comprises revenue recognised by the company in respect of sales and management and expense recharges during the year, exclusive of Value Added Tax.

Sale of goods

Turnover from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.4

OPERATING LEASES: THE COMPANY AS LESSEE

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.5

RESEARCH AND DEVELOPMENT

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic life, if known, or over 10 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.6

INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

 
2.7

PENSIONS

DEFINED CONTRIBUTION PENSION PLAN

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.8

INTANGIBLE ASSETS

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.9

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
20%
Motor vehicles
-
20%
Office equipment
-
33%
Computer equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.10

IMPAIRMENT OF FIXED ASSETS AND GOODWILL

Assets that are subject to depreciation or amortisation are assessed at each balance sheet date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each balance sheet date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.

Page 5

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.11

STOCKS

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.12

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.13

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.14

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 8 (2023 - 1).

Page 6

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4.


INTANGIBLE ASSETS




Intellectual property

£



COST


Additions
25,000



At 31 December 2024

25,000



AMORTISATION


Impairment charge
25,000



At 31 December 2024

25,000



NET BOOK VALUE



At 31 December 2024
-



At 31 December 2023
-



Page 7

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5.


TANGIBLE FIXED ASSETS





Plant and machinery
Motor vehicles
Office equipment
Computer equipment
Total

£
£
£
£
£



COST


Additions
14,258
34,995
3,088
12,990
65,331



At 31 December 2024

14,258
34,995
3,088
12,990
65,331



DEPRECIATION


Charge for the year on owned assets
2,178
2,333
802
3,186
8,499



At 31 December 2024

2,178
2,333
802
3,186
8,499



NET BOOK VALUE



At 31 December 2024
12,080
32,662
2,286
9,804
56,832



At 31 December 2023
-
-
-
-
-


6.


DEBTORS

2024
2023
£
£


Trade debtors
32,354
-

Other debtors
146,305
-

Called up share capital not paid
53,851
-

Prepayments and accrued income
45,052
-

277,562
-


The called up share not paid as at year end was paid shortly after the balance sheet date.
Included within other debtors is £133,011 of unpaid share premium, which was paid shortly after the balance sheet date.

Page 8

 
FLUIDIC SCIENCES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024
2023
£
£

Other loans
528
-

Trade creditors
39,986
-

Accruals and deferred income
11,858
1,028

52,372
1,028



8.


SHARE CAPITAL

2024
2023
£
£
ALLOTTED, CALLED UP AND FULLY PAID



837,097 (2023 - 1) A Ordinary shares of £1.00 each
837,097
1
171,996 (2023 - NIL) B Ordinary shares of £1.00 each
171,996
-

1,009,093

1


On 16 February 2024, 325,000 A Ordinary shares were issued at par.
On 18 March 2024, 255,999 A Ordinary and 164,000 B Ordinary shares were issued at a price per share of £1.25.
On 17 May 2024, 120,000 A Ordinary shares were issued at a price per share of £1.25.
On 24 December 2024, 136,097 A Ordinary and 7,996 B Ordinary shares were issued at a price per share of £3.47.

 
Page 9